Relay Therapeutics, Inc. Contract Liability (Deferred Revenue)
Relay Therapeutics, Inc. (RLAY) had Contract Liability (Deferred Revenue) of $83.00 thousand as of 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2023-02-23
- 2022-06-30: Contract with Customer, Liability, Current $83.00K.
- 2022-03-31: Contract with Customer, Liability, Current $166.00K.
- 2021-12-31: Contract with Customer, Liability, Current $248.00K.
- 2021-09-30: Contract with Customer, Liability, Current $331.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2022-06-30 | $83.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $166.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $248.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | $331.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $414.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |